III.4 Tamoxifen and the uterus: Potential uterine risks of anti- oestrogens. The approach of the European Institute of Oncology

European Journal of Cancer

Volumn 34, Issue SUPPL. 4, 1998, Pages

  Franchi, D ^a   Colombo, N N ^a   Bocciolone, L ^a   Maggioni, A ^a   Costa, A ^a   Sacchini, V ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

ADULT; BREAST CANCER; CANCER RISK; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HYSTEROGRAPHY; MAJOR CLINICAL STUDY; POLYP; PRIORITY JOURNAL; ULTRASOUND THERAPY; UTERUS CANCER;

EID: 0031708923     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00102-6     Document Type: Conference Paper

References (3)

1. De Muylder X, Neven P, De Somer M. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Pathol 1991, 36, 127-129.
2. Granberg S, Wikland M, Karlsson B, et al. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991, 164, 47-52.
3. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994, 170, 447-451.